Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.0K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.0K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.0K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Angina IV: Management01:26

Angina IV: Management

359
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
359

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Arerugi = [Allergy]·2026
Same author

Classification of angioedema types using decision tree modeling.

Frontiers in immunology·2026
Same author

Reference intervals for functional lymphocyte proliferation studies using <sup>3</sup>H thymidine uptake in adults.

Journal of immunological methods·2025
Same author

Factors contributing to non-compliance with on-demand treatment guidelines in hereditary angioedema.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2025
Same author

Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment.

Clinical reviews in allergy & immunology·2025
Same author

A multi-centre UK-based survey on angioedema secondary to acquired C1 inhibitor deficiency.

Clinical and experimental immunology·2025

Related Experiment Video

Updated: Feb 27, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

39.5K

Prophylactic Therapy for Hereditary Angioedema.

Hilary Longhurst1, Emily Zinser1

  • 1Department of Immunology, Barts Health NHS Trust, Pathology and Pharmacy Building, 80 Newark Street, London E1 2HS, UK.

Immunology and Allergy Clinics of North America
|July 9, 2017
PubMed
Summary

Long-term prophylaxis for hereditary angioedema presents challenges. While attenuated androgens are effective, new therapies show promise for improved long-term hereditary angioedema management.

Keywords:
AndrogensC1 inhibitorHereditary angioedemaProgestagensProphylaxisTranexamic acid

More Related Videos

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.6K
An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
08:25

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

2.7K

Related Experiment Videos

Last Updated: Feb 27, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

39.5K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.6K
An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
08:25

An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation

Published on: April 27, 2021

2.7K

Area of Science:

  • Immunology
  • Genetics
  • Pharmacology

Background:

  • Hereditary angioedema (HAE) management requires long-term prophylaxis.
  • Current prophylaxis options, like attenuated androgens, have significant side effect limitations.
  • Tranexamic acid and progestagens have limited evidence but favorable side effect profiles.
  • C1 inhibitor is effective but requires intravenous administration and dose titration.
  • Short-term prophylaxis is recommended for all procedures.

Purpose of the Study:

  • To review current challenges and options for long-term prophylaxis in hereditary angioedema.
  • To evaluate the efficacy and side effect profiles of existing and emerging HAE therapies.
  • To highlight the need for improved long-term prophylaxis strategies.

Main Methods:

  • Review of existing literature on hereditary angioedema prophylaxis.
  • Analysis of efficacy and safety data for various treatment options.
  • Discussion of current challenges and future therapeutic directions.

Main Results:

  • Attenuated androgens are effective but associated with side effects.
  • Tranexamic acid and progestagens offer alternative options with fewer side effects, particularly for specific populations.
  • C1 inhibitor requires careful administration and titration.
  • Newer therapies are emerging with the potential to address current prophylaxis challenges.

Conclusions:

  • Long-term prophylaxis for hereditary angioedema remains challenging.
  • A range of options exist, each with specific benefits and drawbacks.
  • Tranexamic acid and progestagens are viable alternatives for select patients.
  • Intravenous C1 inhibitor requires individualized dosing.
  • Emerging therapies offer hope for more effective and tolerable long-term HAE management.